Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Oncology|April 16, 1998
Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trialA Sandler, S Fox, T Meyers, et al.
The Journal of Urology|February 24, 2009
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomyD R Shepard, R Dreicer, J Garcia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenibI Tamaskar, R Bukowski, P Elson, et al.
Investigational New Drugs|October 22, 2008
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failureR Dreicer, W M Stadler, F R Ahmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1989
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancerG Falkson, R S Gelman, R Dreicer, et al.
Prostate Cancer and Prostatic Diseases|July 15, 2015
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancerA J Pantuck, C A Pettaway, R Dreicer, et al.
Investigational New Drugs|November 15, 2006
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumorsS Kalmadi, M Davis, A Dowlati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2011
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaM D Galsky, G J Chen, W K Oh, et al.
The Journal of Urology|November 1, 1994
Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrenceD Kahn, R D Williams, D W Seldin, et al.
Cancer|April 3, 2001
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesJ R Berenson, L S Rosen, A Howell, et al.
Pageof 6